Grifols (GIKLY) Interest & Investment Income (2010 - 2018)
Grifols (GIKLY) reported Interest & Investment Income of $8.4 million for Q2 2018, up 83.74% on a YoY basis from $4.6 million in Q2 2017, and up 83.74% quarter-over-quarter from $4.6 million in Q2 2017.
Grifols (GIKLY) Interest & Investment Income (2010 - 2018) Analysis & Trends
Grifols has reported Interest & Investment Income for 9 years, with the latest figure at $8.4 million in Q2 2018.
- For the quarter ending Q2 2018, Interest & Investment Income rose 83.74% year-over-year to $8.4 million; the trailing twelve-month figure through Jun 2018 stood at $8.4 million (up 83.74% YoY), and the FY2025 full-year result was $39.6 million, down 15.83% from the prior year.
- Interest & Investment Income for Q2 2018 stood at $8.4 million, up from $4.6 million in the prior quarter.
- The five-year high for Interest & Investment Income was $8.4 million in Q2 2018, with the low at $1.6 million in Q1 2015.
- Historically, Interest & Investment Income has averaged $4.5 million across 5 years, with a median of $4.4 million in 2016.
- Annual changes were most pronounced in 2014 — Interest & Investment Income plunged 42.12% — and 2018, when it jumped 83.74%.
- Grifols' Interest & Investment Income stood at $3.8 million in 2014, then rose by 23.68% to $4.7 million in 2015, then jumped by 59.22% to $7.6 million in 2016, then plunged by 39.38% to $4.6 million in 2017, then soared by 83.74% to $8.4 million in 2018.
- The last three Interest & Investment Income figures came in at $8.4 million (Q2 2018), $4.6 million (Q2 2017), and $7.6 million (Q3 2016), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int & Inv Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Gsk | 93,699,046.73 Bn | 93,699,041.77 Bn | 7.76 Bn | 29.66 Mn |
| 2 | Eli Lilly | 1,012.06 Bn | 1,006.77 Bn | 16.22 Bn | - |
| 3 | Johnson & Johnson | 560.67 Bn | 538.62 Bn | 15.96 Bn | 229.00 Mn |
| 4 | AbbVie | 402.20 Bn | 392.85 Bn | 10.78 Bn | -645.00 Mn |
| 5 | Merck | 298.59 Bn | 292.94 Bn | 12.09 Bn | - |
| 6 | Amgen | 188.77 Bn | 176.74 Bn | 5.87 Bn | - |
| 7 | Gilead Sciences | 160.22 Bn | 152.49 Bn | 5.52 Bn | - |
| 8 | Pfizer | 148.19 Bn | 135.42 Bn | -1.21 Bn | - |
| 9 | Bristol Myers Squibb | 116.72 Bn | 106.26 Bn | 8.07 Bn | - |
| 10 | Grifols | - | - | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2018 | 8.41 Mn |
| Jun 30, 2017 | 4.58 Mn |
| Sep 30, 2016 | 7.55 Mn |
| Jun 30, 2016 | 4.43 Mn |
| Mar 31, 2016 | 2.11 Mn |
| Sep 30, 2015 | 4.74 Mn |
| Jun 30, 2015 | 3.39 Mn |
| Mar 31, 2015 | 1.58 Mn |
| Dec 31, 2014 | 3.84 Mn |
| Dec 31, 2013 | 6.63 Mn |
| Sep 30, 2013 | 5.73 Mn |
| Jun 30, 2013 | 4.52 Mn |
| Mar 31, 2013 | 2.76 Mn |
| Dec 31, 2012 | 2.17 Mn |
| Sep 30, 2012 | 1.21 Mn |
| Jun 30, 2012 | 1.74 Mn |
| Mar 31, 2012 | 3.15 Mn |
| Dec 31, 2011 | 7.76 Mn |
| Sep 30, 2011 | 3.99 Mn |
| Jun 30, 2011 | 2.53 Mn |